Clinical trials: Mild to Moderate COVID-19
Covid19
Off-the-shelf NK Cells (KDS-1000) as Immunotherapy for COVID-19
It is hypothesized that immunotherapy with off-the-shelf NK cells (KDS-1000) early in the course of COVID-19 disease is safe and may augment innate immunity, thereby limiting disease progression and improving survival.
- Trial name
- NCT04797975
- Testing
- KDS-1000
- Sponsor
- Kiadis Pharma
COVID-19, Coronavirus
A Study to Assess Pulsed Inhaled Nitric Oxide vs Placebo in Subjects With Mild or Moderate COVID-19
A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of pulsed inhaled iNO compared to placebo in subjects with COVID-19.
- Conditions
- COVID-19, Coronavirus, Coronavirus Infection
- Trial name
- COViNOX (NCT04421508)
- Testing
- INOpulse
- Where
- 17 sites in United States
- Volunteers
- 191 people
- Sponsor
- Bellerophon Pulse Technologies
Covid-19
Double-blind Study to Evaluate the Safety and Efficacy of Antroquinonol in Mild-Moderate COVID-19 Hospitalized Patients
To evaluate the safety and efficacy of antroquinonol treatment of mild to moderate pneumonia due to COVID-19, as measured by the proportion of patients alive and free of respiratory failure.
- Trial name
- NCT04523181
- Testing
- Antroquinonol
- Where
- 15 sites in United States, Argentina and 1 more
- Volunteers
- 124 people
- Sponsor
- Golden Biotechnology Corporation
COVID-19
A Study to Assess the Safety, Tolerability and Preliminary Efficacy of HH-120 for the Treatment of COVID-19
This is a randomized, double-blind, placebo-controlled Phase 1 study in participants over the age of 18 years with mild to moderate COVID-19.
- Trial name
- NCT06039163
- Testing
- HH-120
- Where
- 4 sites in China
- Volunteers
- 37 people
- Sponsor
- Huahui Health
COVID-19
Evaluation of ADG20 for the Treatment of Mild or Moderate COVID-19
This placebo controlled study is intended to generate safety and efficacy data in order to provide a treatment option for COVID-19 in patients with a high risk of disease progression based on age or co-morbid medical conditions.
- Trial name
- STAMP (NCT04805671)
- Testing
- ADG20, Normal saline
- Where
- 68 sites in Argentina, Brazil and 9 more
- Volunteers
- 399 people
- Sponsor
- Invivyd, Inc.
COVID-19 (Coronavirus Disease 2019)
A US Study to Look at Loss of Work and Healthcare Costs for People Affected With Mild-to-moderate COVID 19 Who Have High Chances of the Disease Becoming Severe
The purpose of this study is to understand how COVID-19 affects people's ability to work and to calculate the costs associated with loss of work.
- Trial name
- NCT07072793
- Testing
- nirmatrelvir-ritonavir
- Where
- United States
- Volunteers
- 131,005 people
- Sponsor
- Pfizer
Sars-CoV2, COVID-19
Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19
This is an open-label, multicenter, parallel-group, randomized, phase III trial that evaluates the efficacy and safety of hydroxychloroquine and favipiravir in the treatment of patients with possible or confirmed COVID-19…
- Trial name
- NCT04411433
- Testing
- Favipiravir (3200 mg + 1200 mg), Favipiravir (3600 mg + 1600 mg), Favipiravir (3200 mg + 1200 mg) combined with Hydroxychloroquine
- Where
- Turkey (Türkiye)
- Volunteers
- 1,008 people
- Sponsor
- Ministry of Health, Turkey
Covid19
Bucillamine in Treatment of Patients With COVID-19
This is a Phase 3, multi-center, randomized, double blind, placebo controlled, clinical study of bucillamine (2 dosage levels) in patients with mild-moderate COVID-19.
- Trial name
- NCT04504734
- Testing
- Bucillamine
- Where
- 47 sites in United States, Puerto Rico
- Volunteers
- 713 people
- Sponsor
- Revive Therapeutics, Ltd.
COVID-19
A Safety and Tolerability Study of BDB-001 in Mild, Moderate COVID-19 Patients
This open, multi-center, multiple ascending dose study was designed to evaluate the safety, tolerability, preliminary efficacy and PK/PD of BDB-001 injection in patients with mild, or general COVID-19.
- Trial name
- NCT05075304
- Testing
- BDB-001 injection
- Where
- 4 sites in China
- Volunteers
- 18 people
- Sponsor
- Staidson (Beijing) Biopharmaceuticals Co., Ltd
SARS-CoV-2 Infection
Study to Evaluate the Efficacy of COVID19-0001-USR in Patients With Mild/or Moderate COVID-19 Infection in Outpatient
Determine the efficacy and safety of COVID19-0001-USR in the treatment of SARS-COV-2 infection in mild to moderate manifestations administered via nebulization/inhalation.
- Trial name
- COVID-19 (NCT04595136)
- Testing
- Drug COVID19-0001-USR, normal saline
- Where
- Colombia
- Volunteers
- 60 people
- Sponsor
- United Medical Specialties
Coronavirus Disease 2019 (COVID-19)
A Study to Evaluate the Efficacy and Safety of Prothione™ Capsules for Mild to Moderate Coronavirus Disease 2019 (COVID-19)
The study is a phase 2 proof of concept study. The purpose of this study is to assess the efficacy and safety of Prothione™ capsules administered orally twice a day for 30 days in subjects with mild to moderate COVID-19.
- Trial name
- NCT04742725
- Testing
- Prothione™ (6g)
- Where
- Rwanda
- Volunteers
- 231 people
- Sponsor
- Prothione, LLC
COVID-19
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
The purpose of this study is to learn about the side effects (safety) of the study medicine PF-07321332 (nirmatrelvir)/ritonavir for the treatment of mild to moderate COVID-19 infection in adults with severe renal impairment.
- Trial name
- NCT05487040
- Testing
- PF-07321332 (nirmatrelvir)/ritonavir
- Where
- 52 sites in United States
- Volunteers
- 15 people
- Sponsor
- Pfizer
COVID 19, Thromboembolic and Bleeding Complications
Thromboembolic Complications in Mild Covid-19 Cases
The aim of the study is to investigate the frequency of thromboembolic complications and the factors influencing them in COVID-19 cases that did not require hospitalization.
- Conditions
- COVID 19, Thromboembolic and Bleeding Complications, Thromboembolism, Venous, Post COVID-19
- Trial name
- NCT06695377
- Where
- Turkey (Türkiye)
- Volunteers
- 961 people, healthy volunteers welcome
- Sponsor
- Marmara University Pendik Training and Research Hospital
Covid19
Oral Camostat Compared With Standard Supportive Care in Mild-Moderate COVID-19 Patients
This study will evaluate the efficacy of oral Foipan® (camostat mesilate) compared with the current standard of care in reducing the duration of viral shedding of SARS-CoV-2 virus in patients with mild-moderate COVID-19 disease.
- Trial name
- COPS-2003 (NCT04524663)
- Testing
- Camostat Mesilate, Standard of Care Treatment
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Stanford University
Covid19
Study of TB006 in Outpatient Patients With Mild to Moderate COVID-19
TB006, a monoclonal antibody, is an anti-inflammatory and anti-fibrotic agent that reduces the severity of underlying diseases in COVID-19 patients.
- Trial name
- NCT04801056
- Testing
- TB006
- Sponsor
- TrueBinding, Inc.
COVID-19
Evaluating the Safety and Efficacy of AD17002 Intranasal Spray in Treating Participants With Mild to Moderate COVID-19
AD17002 enhances nasal mucosal innate immunity and has met safety and efficacy endpoints in studies of nasal adjuvants or intranasal immunomodulators.
- Trial name
- NCT05541510
- Testing
- AD17002 + Formulation buffer
- Where
- 3 sites in Indonesia
- Volunteers
- 180 people
- Sponsor
- Advagene Biopharma Co. Ltd.
COVID-19
Pilot Clinical Trial to Explore Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients
This study is a multi-center, single-arm, open-label, pilot clinical trial to explore efficacy and safety of Pyramax in mild to moderate COVID-19 patients
- Trial name
- NCT05633420
- Testing
- Pyramax
- Where
- 2 sites in South Korea
- Volunteers
- 20 people
- Sponsor
- Shin Poong Pharmaceutical Co. Ltd.
COVID-19
Efficacy and Safety of JT001 (VV116) Compared With Paxlovid
The purpose of this study is to evaluate the efficacy and safety of JT001 (VV116) Compared With Paxlovid for the Treatment of Coronavirus Disease 2019 (COVID-19) in Participants With Mild to Moderate COVID-19.
- Trial name
- NCT05341609
- Testing
- JT001, Paxlovid
- Where
- 7 sites in China
- Volunteers
- 822 people
- Sponsor
- Vigonvita Life Sciences
SARS-CoV2
CANnabiDiol for CoviD-19 pATiEnts With Mild to Moderate Symptoms
The aim of this work is to conduct a randomized, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of cannabidiol (CBD - 300 mg a day) in patients infected with SARS-CoV-2.
- Trial name
- CANDIDATE (NCT04467918)
- Testing
- Cannabidiol
- Where
- 2 sites in Brazil
- Volunteers
- 100 people
- Sponsor
- University of Sao Paulo
Covid19
A Pilot Study on Efficacy and Safety of Ayurveda Combination in Patients With Mild-to-Moderate COVID-19
The COVID-19 pandemic is considered as the most crucial global health concern of the century. Given the complex interaction of physical and social factors on fast spreading infection, there have been increasing calls for…
- Trial name
- NCT04621903
- Where
- United Kingdom
- Volunteers
- 26 people
- Sponsor
- Aarogyam UK